Ginsenoside Rg5 attenuates hypoxia-induced cardiomyocyte apoptosis via regulating the Akt pathway
- PMID: 36762503
- DOI: 10.1111/cbdd.14217
Ginsenoside Rg5 attenuates hypoxia-induced cardiomyocyte apoptosis via regulating the Akt pathway
Abstract
Ginsenoside Rg5 has been implicated in a variety of diseases. However, it is unknown whether Ginsenoside Rg5 can protect against hypoxia-induced neonatal rat cardiomyocytes (NRMs). The purpose of this study was to look into the effect of Ginsenoside Rg5 on hypoxia-induced NRMs apoptosis as well as the underlying molecular mechanism. In this study, following isolation and culture of ventricular myocardial cells from neonatal rats, the appropriate concentration of Rg5 was determined using the MTT assay, the effect of Rg5 on apoptosis was assessed employing TUNEL staining and flow cytometry assays. Levels of apoptosis-related proteins and phosphorylated level of Akt (ser 473 and ser 308) were analyzed using the western blot analysis. Finally, the experimental results shown that Ginsenoside Rg5 significantly inhibited hypoxia-induced NRMs apoptosis, decreased the expression pro-apoptotic protein Bax, increased the expression of anti-apoptotic protein Bcl-2 ratio and the level of cleaved caspase 3. Akt signaling activation was found to be the mechanism of Ginsenoside Rg5s protective effect on hypoxia-induced NRMs apoptosis, as an Akt inhibitor eliminated the anti-apoptotic effects of Ginsenoside Rg5. Various analyses were performed and verified, ginsenoside Rg5 suppressed hypoxia-induced apoptosis in NRMs via activation of the Akt signaling.
Keywords: Akt; apoptosis; ginsenoside Rg5; neonatal rat cardiomyocytes.
© 2023 John Wiley & Sons Ltd.
Similar articles
-
[Ginsenoside-Rg5 Synergizes with Imatinib to Enhances the Anti-Chronic Myeloid Leukemia K562 Cell Activity through PI3K/AKT/mTOR Pathway].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Feb;33(1):1-8. doi: 10.19746/j.cnki.issn.1009-2137.2025.01.001. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025. PMID: 40017179 Chinese.
-
Ginsenoside-Rg5 Inhibits Retinoblastoma Proliferation and Induces Apoptosis through Suppressing BCL2 Expression.Chemotherapy. 2018;63(5):293-300. doi: 10.1159/000495575. Epub 2019 Feb 7. Chemotherapy. 2018. PMID: 30731458
-
Ginsenoside Rg5 increases cardiomyocyte resistance to ischemic injury through regulation of mitochondrial hexokinase-II and dynamin-related protein 1.Cell Death Dis. 2017 Feb 23;8(2):e2625. doi: 10.1038/cddis.2017.43. Cell Death Dis. 2017. PMID: 28230856 Free PMC article.
-
Targeting Akt/CREB/BDNF signaling pathway by ginsenosides in neurodegenerative diseases: A mechanistic approach.Pharmacol Res. 2022 Mar;177:106099. doi: 10.1016/j.phrs.2022.106099. Epub 2022 Jan 26. Pharmacol Res. 2022. PMID: 35092819 Review.
-
Ginsenoside Rg5 as an anticancer drug: a comprehensive review on mechanisms, structure-activity relationship, and prospects for clinical advancement.Pharmacol Rep. 2024 Apr;76(2):287-306. doi: 10.1007/s43440-024-00586-5. Epub 2024 Mar 25. Pharmacol Rep. 2024. PMID: 38526651 Review.
Cited by
-
Ginsenoside Rg5 alleviates hypoxia-induced myocardial apoptosis by targeting STAT3 to promote Tyr705 phosphorylation.Chin Med. 2025 Jun 13;20(1):86. doi: 10.1186/s13020-025-01128-8. Chin Med. 2025. PMID: 40514732 Free PMC article.
References
REFERENCES
-
- Chen, J. (2012). Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World Journal of Virology., 1(6), 154-161.
-
- Choi, S. Y., Kim, K. J., Song, J. H., & Lee, B. Y. (2018). Ginsenoside Rg5 prevents apoptosis by modulating heme-oxygenase-1/nuclear factor E2-related factor 2 signaling and alters the expression of cognitive impairment-associated genes in thermal stress-exposed HT22 cells. Journal of Ginseng Research, 42(2), 225-228.
-
- Corbalán, R. (2021). Optimizing treatment for acute myocardial infarction, a continuous effort. Arquivos Brasileiros de Cardiologia, 117(6), 1079-1080.
-
- Cui, Y., Su, Y., Deng, L., & Wang, W. (2018). Ginsenoside-Rg5 inhibits retinoblastoma proliferation and induces apoptosis through suppressing BCL2 expression. Chemotherapy, 63(5), 293-300.
-
- Dean, L. (2012). Vemurafenib therapy and BRAF and NRAS genotype. In V. Pratt, H. McLeod, W. Rubinstein, L. Dean, B. Kattman, & A. Malheiro (Eds.), Medical Genetics Summaries. Bethesda (MD).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials